– Recipients include 20 individuals living with Duchenne muscular dystrophy and five siblings of individuals living with Duchenne
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne muscular dystrophy and five to siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000.
“On behalf of Sarepta and the selection committee, we are thrilled to announce the recipients of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. From small private colleges to some of the largest research universities in the world, this class of recipients were impressive for their academic success, profound curiosity, commitment to learning and fierce determination,” said Diane Berry, Ph.D., executive vice president and Chief Global Policy & Advocacy Officer, Sarepta. “Over the past seven years, Sarepta has awarded nearly 140 scholarships through the Route 79 program. We are honored to support the growth of these young adults as they begin the next chapter of their academic journey.”
The Route 79 program was created in 2018 to recognize exceptional individuals living with Duchenne as they pursue their post-secondary education. In 2022, Sarepta expanded the program to include siblings of individuals with Duchenne in recognition of the impact that a diagnosis of Duchenne may have on the entire family. Recipients of the scholarship are chosen by an independent selection committee composed of Duchenne community members, who consider each applicant’s community involvement, academic achievements, and personal essay. In addition to application review by the independent committee, submissions are de-identified for the selection committee with no indication of whether the candidate has received, or plans to receive, a Sarepta therapy.
2024-2025 Route 79 Scholarship Recipients
John “Jack” Becker, Embry-Riddle Aeronautical University, Daytona Beach
Jacob Colby, The Evergreen State College
Kyle Cox, Texas A&M University
Bradon Coy, University of Florida
John Herzfeld, Arizona State University, Downtown Phoenix
Declan Hickey, Curry College
Elliott Johnson, Lebanon Valley College
Henry Johnson, Temple University
Ryan Lugo, State University of New York at New Paltz
John McConnell, Boise State University
Josh Pflueger, Texas Christian University
Ryan Schultz, Rowan University
Jasdeep Singh, Cleveland Institute of Art
Parker Strobeck, North Arkansas College
Robert Sullivan, John Carroll University
William Sun, University of California, Davis
Braden Van Eperen, Union College
Connor Vassigh, Lone Star College System
Max Vertin, Hastings College
Jack Wolf, University of Dayton
2024-2025 Route 79 Sibling Scholarship Recipients
Abraham Dreher, Bennington College
Addison Griffin, Auburn University
Mateo Ramirez Laverde Guzman, University of North Carolina at Chapel Hill
Alexis Udell, University of Wisconsin-Madison
Austin Vassigh, Texas A&M University
About Route 79, The Duchenne Scholarship Program
The Route 79 program is designed to help students living with Duchenne and siblings of individuals living with Duchenne pursue their post-secondary educational goals. Scholarship recipients are chosen by an independent committee of Duchenne community members based on an applicant’s community involvement, personal essay, and recommendation letter. The underlying cause of Duchenne is a difference in the gene coding for dystrophin. Dystrophin is an essential protein that plays a pivotal role in muscle structure, function and preservation. The numerical significance of the scholarship’s name, Route 79, ties to the 79 exons of the dystrophin gene. For more information, visit sarepta.com/route79.
About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook.
Internet Posting of Information
We routinely post information that may be important to investors in the ‘For Investors’ section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Contacts
Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
